Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Asianet Newsable on MSN1d
Ban ads of high sugar, fat products targeting children: Milind Deora praises PM's anti-obesity campaign| WATCHShiv Sena MP and Rajya Sabha member Milind Deora praised Prime Minister Narendra Modi for the Anti Obesity campaign in his ...
Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.
Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...
Overweight and obesity rates in adults, children and teens more than doubled over the past three decades, afflicting 2.1 billion adults and 493 million young people with excess weight, researchers ...
The way we think about obesity is changing. A new definition and diagnostic framework for obesity has been put forward in a commission published by The Lancet Diabetes & Endocrinology, recognizing ...
‘Overweight, including obesity, overtook tobacco use as the leading risk factor in 2024, driven by a substantial fall (41%) ...
Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback